The breakthrough CAR-T personalized leukemia therapy devised by Professor Zelig Eshhar of Israel’s Weizmann Institute (see here) is now available in the UK. The National Health Service will fund Kymriah – the CAR-T treatment commercialized by Novartis.
https://www.telegraph.co.uk/news/2018/09/04/nhs-fund-game-changing-personalised-cancer-drug/